Last reviewed · How we verify
MK0826; ertapenem sodium
At a glance
| Generic name | MK0826; ertapenem sodium |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (PHASE2)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Antibiotic Concentrations Among Critically Ill Patients
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0826; ertapenem sodium CI brief — competitive landscape report
- MK0826; ertapenem sodium updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI